Patent
The invention refers to an isolated antibody that specifically binds to O25b antigen of E. coli strains comprising at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in FIG. 1 , and optionally further comprising an antibody light chain variable region (VL), which comprises any of the CDR4 to CDR6 sequences as listed in FIG. 1 , or functionally active CDR variants of any of the forgoing CDR 1-6 sequences.
1. An isolated antibody that specifically binds to O25b antigen of Escherichia coli ( E. coli ) strains, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL are identical to the VH and VL of a monoclonal antibody comprising:
a) a heavy chain (HC) sequence identified as SEQ ID NO:200; and a light chain (LC) sequence identified as SEQ ID NO:264;
b) a HC sequence identified as SEQ ID NO:201; and a LC sequence identified as SEQ ID NO: 265;
c) a HC sequence identified as SEQ ID NO:202; and a LC sequence identified as SEQ ID NO: 266;
d) a HC sequence identified as SEQ ID NO:203; and a LC sequence identified as SEQ ID NO: 267;
e) a HC sequence identified as SEQ ID NO:204; and a LC sequence identified as SEQ ID NO: 268;
f) a HC sequence identified as SEQ ID NO:205; and a LC sequence identified as SEQ ID NO: 269;
g) a HC sequence identified as SEQ ID NO:206; and a LC sequence identified as SEQ ID NO: 270;
h) a HC sequence identified as SEQ ID NO:207; and a LC sequence identified as SEQ ID NO: 271;
i) a HC sequence identified as SEQ ID NO:208; and a LC sequence identified as SEQ ID NO: 272;
j) a HC sequence identified as SEQ ID NO:209; and a LC sequence identified as SEQ ID NO: 273;
k) a HC sequence identified as SEQ ID NO:210; and a LC sequence identified as SEQ ID NO: 274;
l) a HC sequence identified as SEQ ID NO:211; and a LC sequence identified as SEQ ID NO: 275;
m) a HC sequence identified as SEQ ID NO:212; and a LC sequence identified as SEQ ID NO: 276;
n) a HC sequence identified as SEQ ID NO:213; and a LC sequence identified as SEQ ID NO: 277;
o) a HC sequence identified as SEQ ID NO:214; and a LC sequence identified as SEQ ID NO: 278;
p) a HC sequence identified as SEQ ID NO:215; and a LC sequence identified as SEQ ID NO: 279;
q) a HC sequence identified as SEQ ID NO:314; and a LC sequence identified as SEQ ID NO: 318; or
r) a HC sequence identified as SEQ ID NO:315; and a LC sequence identified as SEQ ID NO: 319.
2. An isolated antibody that specifically binds to O25b antigen of Escherichia coli ( E. coli ) strains, comprising an antibody heavy chain (HC) and light chain (LC) selected from the group consisting of:
a) a heavy chain (HC) sequence identified as SEQ ID NO:200; and a light chain (LC) sequence identified as SEQ ID NO:264;
b) a HC sequence identified as SEQ ID NO:201; and a LC sequence identified as SEQ ID NO: 265;
c) a HC sequence identified as SEQ ID NO:202; and a LC sequence identified as SEQ ID NO: 266;
d) a HC sequence identified as SEQ ID NO:203; and a LC sequence identified as SEQ ID NO: 267;
e) a HC sequence identified as SEQ ID NO:204; and a LC sequence identified as SEQ ID NO: 268;
f) a HC sequence identified as SEQ ID NO:205; and a LC sequence identified as SEQ ID NO: 269;
g) a HC sequence identified as SEQ ID NO:206; and a LC sequence identified as SEQ ID NO: 270;
h) a HC sequence identified as SEQ ID NO:207; and a LC sequence identified as SEQ ID NO: 271;
i) a HC sequence identified as SEQ ID NO:208; and a LC sequence identified as SEQ ID NO: 272;
j) a HC sequence identified as SEQ ID NO:209; and a LC sequence identified as SEQ ID NO: 273;
k) a HC sequence identified as SEQ ID NO:210; and a LC sequence identified as SEQ ID NO: 274;
l) a HC sequence identified as SEQ ID NO:211; and a LC sequence identified as SEQ ID NO: 275;
m) a HC sequence identified as SEQ ID NO:212; and a LC sequence identified as SEQ ID NO: 276;
n) a HC sequence identified as SEQ ID NO:213; and a LC sequence identified as SEQ ID NO: 277;
o. a HC sequence identified as SEQ ID NO:214; and a LC sequence identified as SEQ ID NO: 278;
p) a HC sequence identified as SEQ ID NO:215; and a LC sequence identified as SEQ ID NO: 279;
q) a HC sequence identified as SEQ ID NO:314; and a LC sequence identified as SEQ ID NO: 318; or
r) a HC sequence identified as SEQ ID NO:315; and a LC sequence identified as SEQ ID NO: 319.
3. A pharmaceutical composition comprising the isolated antibody of claim 1 and a pharmaceutically acceptable carrier or excipient.
4. A pharmaceutical composition comprising the isolated antibody of claim 2 and a pharmaceutically acceptable carrier or excipient.